文献速递慢性肾脏病

代谢组学分析改进肾小球滤过率估算:一项概念验证研究

Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本研究在200例AASK和265例MESA参与者中,利用血清代谢组学筛选与实测GFR相关的代谢物,并开发靶向检测组合。在AASK开发、MESA验证的代谢物组合估算eGFR,其误差>30%的比例(1-P30)分别为3.7%和1.9%,优于eGFRcr(11.2%和18.5%)和eGFRcys,但与联合肌酐和胱抑素C的eGFR相比未一致更优。

要点

  • 多代谢物组合可提高GFR估算准确性,误差>30%比例低于eGFRcr。
  • 排除肌酐和人口学特征的代谢物组合仍表现良好,有望作为确认试验。
  • 在eGFRcr不可靠时,代谢组学方程可能提供补充价值。

核心结论

  • 多代谢物组合能够实现准确的GFR估算,优于eGFRcr和eGFRcys。
  • 排除肌酐和人口学特征的代谢组学方程应进一步测试稳健性和普适性。

研究设计与样本

  • 横断面研究,纳入200例AASK和265例MESA参与者,均具有实测GFR。
  • 采用非靶向气相色谱/双质谱和液相色谱/双质谱定量,并开发15种代谢物的靶向检测。

主要发现

  • AASK中283/780(36%)和MESA中387/1447(27%)的非靶向代谢物与mGFR显著相关(P ≤ 0.001)。
  • AASK开发、MESA验证的靶向代谢物组合eGFR的1-P30分别为3.7%和1.9%,优于eGFRcr(11.2%和18.5%,P < 0.001)和eGFRcys(10.6%和9.1%,P = 0.02和P < 0.05)。
  • 与联合肌酐和胱抑素C的eGFR相比,代谢物组合在AASK中1-P30为3.7%(P > 0.05),在MESA中为9.1%(P < 0.05)。
  • 排除肌酐和人口学特征的代谢物组合与eGFRcr相比,1-P30在AASK为6.4%(P = 0.11),在MESA为3.4%(P < 0.001)。

临床怎么用

  • 在eGFRcr不可靠时,可考虑代谢组学方程作为潜在的确认试验。
  • 优先选择排除肌酐和人口学特征的代谢物组合,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estimation of glomerular filtration rate (GFR) using estimated glomerular filtration rate creatinine (eGFRcr) is central to clinical practice but has limitations. We tested the hypothesis that serum metabolomic profiling can identify novel markers that in combination can provide more accurate GFR estimates. METHODS: We performed a cross-sectional study of 200 African American Study of Kidney Disease and Hypertension (AASK) and 265 Multi-Ethnic Study of Atherosclerosis (MESA) participants with measured GFR (mGFR). Untargeted gas chromatography/dual mass spectrometry- and liquid chromatography/dual mass spectrometry-based quantification was followed by the development of targeted assays for 15 metabolites. On the log scale, GFR was estimated from single- and multiple-metabolite panels and compared with eGFR using the Chronic Kidney Disease Epidemiology equations with creatinine and/or cystatin C using established metrics, including the proportion of errors >30% of mGFR (1-P30), before and after bias correction. RESULTS: Of untargeted metabolites in the AASK and MESA, 283 of 780 (36%) and 387 of 1447 (27%), respectively, were significantly correlated (P ≤ 0.001) with mGFR. A targeted metabolite panel eGFR developed in the AASK and validated in the MESA was more accurate (1-P30 3.7 and 1.9%, respectively) than eGFRcr [11.2 and 18.5%, respectively (P < 0.001 for both)] and estimating GFR using cystatin C (eGFRcys) [10.6% (P = 0.02) and 9.1% (P < 0.05), respectively] but was not consistently better than eGFR using both creatinine and cystatin C [3.7% (P > 0.05) and 9.1% (P < 0.05), respectively]. A panel excluding creatinine and demographics still performed well [1-P30 6.4% (P = 0.11) and 3.4% (P < 0.001) in the AASK and MESA] versus eGFRcr. CONCLUSIONS: Multimetabolite panels can enable accurate GFR estimation. Metabolomic equations, preferably excluding creatinine and demographic characteristics, should be tested for robustness and generalizability as a potential confirmatory test when eGFRcr is unreliable.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Coresh J, Inker LA, Sang Y, et al. Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. Nephrol Dial Transplant. 2019. PMID: 29718360. doi:10.1093/ndt/gfy094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。